Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2026-05-15 4:47 pm Sale | 2026-03-31 | 13G | ACRIVON THERAPEUTICS INC ACRV | Citadel Advisors LLC | 13 0.000% | -1,721,854 (-100.00%) | Filing History |
| 2026-04-23 4:29 pm Purchase | 2026-04-22 | 13D | ACRIVON THERAPEUTICS INC ACRV | RA CAPITAL MANAGEMENT L.P. | 12,284,906 28.800% | 3,888,888 (+46.32%) | Filing History |
| 2026-03-23 4:28 pm Purchase | 2026-03-19 | 13D | ACRIVON THERAPEUTICS INC ACRV | RA CAPITAL MANAGEMENT L.P. | 8,396,018 21.600% | 36,916 (+0.44%) | Filing History |
| 2025-11-21 5:36 pm Purchase | 2025-11-14 | 13G | ACRIVON THERAPEUTICS INC ACRV | Citadel Advisors LLC | 1,721,867 5.500% | 180,502 (+11.71%) | Filing History |
| 2025-11-14 4:07 pm Sale | 2025-09-30 | 13G | ACRIVON THERAPEUTICS INC ACRV | Citadel Advisors LLC | 1,541,365 4.900% | -354,253 (-18.69%) | Filing History |
| 2025-08-13 11:12 am Purchase | 2025-06-30 | 13G | ACRIVON THERAPEUTICS INC ACRV | Sands Capital Life Sciences Pulse Fund II, L.P. | 2,122,605 6.800% | 469,999 (+28.44%) | Filing History |
| 2025-06-04 4:05 pm Sale | 2025-06-02 | 13G | ACRIVON THERAPEUTICS INC ACRV | PERCEPTIVE ADVISORS LLC | 0 0.000% | -3,104,139 (Position Closed) | Filing History |
| 2025-05-15 5:24 pm Purchase | 2025-03-31 | 13G | ACRIVON THERAPEUTICS INC ACRV | Citadel Advisors LLC | 1,895,618 6.000% | 245,954 (+14.91%) | Filing History |
| 2025-05-01 8:21 pm Sale | 2025-04-29 | 13G | ACRIVON THERAPEUTICS INC ACRV | PERCEPTIVE ADVISORS LLC | 3,104,139 9.900% | -2,256,719 (-42.10%) | Filing History |
| 2024-07-10 8:34 pm Unchanged | 2024-06-30 | 13G | ACRIVON THERAPEUTICS INC ACRV | Chione Ltd. | 3,848,632 12.500% | 0 (Unchanged) | Filing History |
| 2024-07-10 8:29 pm Sale | 2023-12-31 | 13G | ACRIVON THERAPEUTICS INC ACRV | Chione Ltd. | 3,848,632 17.300% | -7,965 (-0.21%) | Filing History |
| 2024-04-15 08:21 am Purchase | 2024-04-11 | 13G | ACRIVON THERAPEUTICS INC ACRV | PERCEPTIVE ADVISORS LLC | 5,360,858 17.400% | 2,353,000 (+78.23%) | Filing History |
| 2024-04-11 4:16 pm Purchase | 2024-04-11 | 13D | ACRIVON THERAPEUTICS INC ACRV | RA CAPITAL MANAGEMENT L.P. | 8,359,102 27.100% | 3,541,743 (+73.52%) | Filing History |
| 2024-02-14 4:57 pm Purchase | 2023-12-31 | 13G | ACRIVON THERAPEUTICS INC ACRV | Citadel Advisors LLC | 1,649,664 7.400% | 15,515 (+0.95%) | Filing History |
| 2024-02-14 4:36 pm Unchanged | 2023-12-31 | 13G | ACRIVON THERAPEUTICS INC ACRV | PERCEPTIVE ADVISORS LLC | 3,007,858 13.600% | 0 (Unchanged) | Filing History |
| 2024-02-14 09:51 am Sale | 2023-12-31 | 13G | ACRIVON THERAPEUTICS INC ACRV | Marshall Wace North America L.P. | 597,469 2.700% | -625,783 (-51.16%) | Filing History |
| 2024-02-13 3:40 pm Sale | 2023-12-31 | 13G | ACRIVON THERAPEUTICS INC ACRV | Sands Capital Alternatives LLC | 1,652,605 7.400% | -1 (-0.00%) | Filing History |
| 2023-03-30 5:07 pm Purchase | 2023-03-28 | 13D | ACRIVON THERAPEUTICS INC ACRV | RA CAPITAL MANAGEMENT L.P. | 4,817,359 22.000% | 3,917 (+0.08%) | Filing History |
| 2023-02-14 3:26 pm Purchase | 2022-12-31 | 13G | ACRIVON THERAPEUTICS INC ACRV | Sands Capital Alternatives LLC | 1,652,606 7.900% | 1,652,606 (New Position) | Filing History |
| 2023-02-14 2:33 pm Unchanged | 2022-12-31 | 13G | ACRIVON THERAPEUTICS INC ACRV | PERCEPTIVE ADVISORS LLC | 3,007,858 14.400% | 0 (Unchanged) | Filing History |